CalciMedica, Inc. (CALC) Operating Margin
- Operating margin · 12 months: Value (m); Formula and calculation Operating income / revenue. Period ending 2026-06-30..
Operating margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Operating margin · 12 months | (m) | Operating income / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating income | -19.63M USD | Operating Income (Loss) |
| Revenue | (m) | |
| Cost of products and services | (m) | |
| Research and development | 12.54M USD | Research and Development Expense |
| Selling, general and administration | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Operating income (USD) | Revenue (USD) | Cost of products and services (USD) | Research and development (USD) | Selling, general and administration (USD) | Operating margin |
|---|---|---|---|---|---|---|
| 2026-06-30 | $-19.63M | (m) | (m) | $12.54M | (m) | (m) |
| 2026-03-31 | $-22.23M | (m) | (m) | $14.49M | (m) | (m) |
| 2025-12-31 | $-23.12M | (m) | (m) | $15.23M | (m) | (m) |
| 2025-09-30 | $-24.91M | (m) | (m) | $15.96M | (m) | (m) |
| 2025-06-30 | $-25.03M | (m) | (m) | $15.65M | (m) | (m) |
| 2025-03-31 | $-24.93M | (m) | (m) | $15.76M | (m) | (m) |
| 2024-12-31 | $-24.20M | (m) | (m) | $14.48M | (m) | (m) |
| 2024-09-30 | $-22.35M | (m) | (m) | $13.43M | (m) | (m) |
| 2024-06-30 | $-21.45M | (m) | (m) | $12.65M | (m) | (m) |
| 2024-03-31 | $-21.50M | (m) | (m) | $12.31M | (m) | (m) |
| 2023-12-31 | $-38.08M | (m) | (m) | $15.86M | (m) | (m) |
| 2023-09-30 | $-58.85M | (m) | (m) | $20.76M | (m) | (m) |
| 2023-06-30 | $-57.30M | (m) | (m) | $19.23M | (m) | (m) |
| 2023-03-31 | $-54.31M | (m) | (m) | $17.68M | (m) | (m) |
| 2022-12-31 | $-36.18M | (m) | (m) | $14.11M | (m) | (m) |
| 2022-09-30 | $-37.17M | (m) | (m) | $17.63M | (m) | (m) |
| 2022-06-30 | $-35.20M | (m) | (m) | $18.40M | (m) | (m) |
| 2022-03-31 | $-34.64M | (m) | (m) | $18.51M | (m) | (m) |
| 2021-12-31 | $-35.95M | (m) | (m) | $18.90M | (m) | (m) |
| 2021-09-30 | $-36.42M | (m) | (m) | $20.12M | (m) | (m) |
| 2021-06-30 | $-35.23M | (m) | (m) | $20.86M | (m) | (m) |
| 2021-03-31 | $-33.52M | (m) | (m) | $21.32M | (m) | (m) |
| 2020-12-31 | $-29.83M | (m) | (m) | $20.96M | (m) | (m) |
| 2020-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-03-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-12-31 | $-37.50M | (m) | (m) | $30.58M | (m) | (m) |
| 2019-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| TALPHERA, INC. (TLPH) | United States | $0.060B | |
| Skye Bioscience, Inc. (SKYE) | United States | $0.061B | -0.48 |
| Boundless Bio, Inc. (BOLD) | United States | $0.059B | -0.88 |
| NOMAD POWER SOLUTIONS, INC. (NMAD) | United States | $0.058B | |
| Rein Therapeutics, Inc. (RNTX) | United States | $0.063B | -1.76 |
| HYPERION DEFI, INC. (HYPD) | United States | $0.065B | |
| Annovis Bio, Inc. (ANVS) | United States | $0.056B | -1.58 |
| XBiotech Inc. (XBIT) | United States | $0.066B | -1.56 |
| HERON THERAPEUTICS, INC. /DE/ (HRTX) | United States | $0.055B | -2.38 |
| Clene Inc. (CLNN) | United States | $0.054B | -1.99 |